Sorin received FDA approval to bring to the U.S. market its Mitroflow aortic heart valve with Phospholipid Reduction Treatment (PRT). Already approved in Europe three years ago, the material treatment is designed to help prevent calcification on the surface of the device by reducing the phospholipid content on the valve.

The Mitroflow valve itself has been around for three decades with a proven track record, and the new phospholipid treatment will hopefully make it last in situ considerably longer than previous models.

Excellent Hemodynamic Performance
-Maximized flow area
-Wide opening
-Synchronous leaflet action
-Uniform mechanical behaviour
-Optimized hemodynamic performance

Ease and Versatility of Implant
-Small, streamlined sewing ring
-Low valve profile
-Valve versatility

Proven Clinical Results
-Unique design since 1982
-Excellent long-term clinical outcomes

Source:Sorin